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A B S T R A C T
Background: Calciﬁc atherosclerosis is a major challenge to intraluminal drug delivery in peripheral artery
disease (PAD).
Objectives: We evaluated the eﬀects of orbital atherectomy on intraluminal paclitaxel delivery to human per-
ipheral arteries with substantial calciﬁed plaque.
Methods: Diagnostic angiography and 3-D rotational imaging of ﬁve fresh human lower limbs revealed calciﬁ-
cation in all main arteries. The proximal or distal segment of each artery was treated using an orbital ather-
ectomy system (OAS) under simulated blood ﬂow and ﬂuoroscopy. Explanted arterial segments underwent ei-
ther histomorphometric assessment of eﬀect or tracking of 14C-labeled or ﬂuorescent–labeled paclitaxel.
Radiolabeled drug quantiﬁed bulk delivery and ﬂuorescent label established penetration of drug over ﬁner
spatial domain in serial microscopic sections. Results were interpreted using a mathematical model of binding-
diﬀusion mediated arterial drug distribution.
Results: Lesion composition aﬀected paclitaxel absorption and distribution in cadaveric human peripheral ar-
teries. Pretreatment imaging calcium scores in control femoropopliteal arterial segments correlated with a log-
linear decline in the bulk absorption rate-constant of 14C-labeled, declining 5.5-fold per calciﬁed quadrant
(p = 0.05, n = 7). Compared to controls, OAS-treated femoropopliteal segments exhibited 180 μm thinner in-
tima (p < 0.001), 45% less plaque calciﬁcation, and 2 log orders higher paclitaxel bulk absorption rate-con-
stants. Correspondingly, ﬂuorescent paclitaxel penetrated deeper in OAS-treated femoropopliteal segments
compared to controls, due to a 70% increase in diﬀusivity (p < 0.001).
Conclusions: These data illustrate that calciﬁed plaque limited intravascular drug delivery, and controlled OAS
treatment of calciﬁc plaques resulted in greater drug permeability and improved adjunct drug delivery to dis-
eased arteries.
1. Introduction
Considerable progress has been made in interventional treatments
of peripheral artery disease (PAD), yet key challenges remain that are
largely attributed to lesion morphology and calciﬁc burden [1]. While
percutaneous transluminal angioplasty relies on plaque fracture and
vessel wall stretching [2], calcium alters morphology and compliance of
the arterial wall reducing the eﬀect of both angioplasty and stent
deployment. Moreover, calciﬁcation increases the occurrence of ﬂow
limiting dissections and acute vessel recoil [3], and limits stent eﬃcacy
by increasing the risk of incomplete stent expansion, malapposition,
and fractures [4]. Paclitaxel coated balloons (PCB) reduce restenosis in
the superﬁcial femoral and popliteal arteries but have not been proved
to be eﬀective in below-the-knee arteries [5,6]. Fanelli et al. [7] ob-
served that late lumen loss and primary patency 12 months following
PCB treatment correlated negatively with the degree of circumferential
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calciﬁcation as assessed by computerized tomographic angiography,
and hypothesized that vessel wall calciﬁcation impedes paclitaxel ab-
sorption. These and other investigators have suggested that vessel
preparation by atherectomy might remove barriers to intravascular
drug absorption and distribution in the artery wall [8]. Arterial plaque
can be removed by a range of intravascular atherectomy devices [9]
that excise it using cutting blades (directional atherectomy) or sand it
down via high speed concentric rotation of a diamond-encrusted el-
liptical burr (rotational atherectomy) or an eccentric crown that orbits
along a spiral path and frictionally pulverizes hard surfaces into
harmless microparticles (orbital atherectomy).
Data on adjunctive directional atherectomy and PCB from a single-
center non-randomized study [10] looked promising, and additional
studies are underway. However, clinical experience with adjunctive
rotational atherectomy and coronary drug eluting stents has been
mixed [11–14] and it remains unclear whether atherectomy did not
enhance drug delivery or whether such beneﬁts existed but were
counterbalanced by restenotic response to the atherectomy related in-
juries [12]. Preclinical experiments are better suited for examining the
barrier eﬀect of plaque on drug absorption and distribution with or
without atherectomy. Unfortunately, induction of mineralization in
animal models has proven diﬃcult and a recent study in atheromatous
arteries in the pig model exhibited comparable paclitaxel deposition
30 days post PCB treatment in OAS-pretreated vs native femoral ar-
teries [15].
The current study was designed to directly quantify the in-
travascular absorption and distribution of paclitaxel in calciﬁc human
peripheral arteries at baseline and after OAS treatment. This design
allowed the quantiﬁcation of the barrier properties of calciﬁc intimal
plaque on paclitaxel absorption and its modulation by arterial plaque
modiﬁcation in femoropoliteal arteries. The study was not designed to
address the impact of medial calciﬁcation on drug absorption. Limited
observations on drug delivery in calciﬁed tibial arteries are reported to
help with future study designs.
2. Methods
2.1. Experimental overview
Five fresh human lower limbs were obtained from a certiﬁed re-
search institution and maintained on ice for further evaluation. 3-D
rotational imaging (GE Healthcare Innova® 2100 Cath Lab, Milwaukee,
Wisconsin, USA) was performed on all limbs to identify the distribution
and severity of calciﬁcation in the lower extremity arteries. Intra-ar-
terial sheaths were inserted proximally and distally to simulate human
arterial blood ﬂow with saline perfusion. Under ﬂuoroscopic guidance,
a guiding catheter was advanced through the sheath into designated
peripheral arteries and angiographic images were obtained to identify
lesion location for OA. The superﬁcial femoral arteries (SFA), popliteal
and tibial arteries were divided through angiographic measurements
into approximately equal segment lengths, and the proximal or distal
segment of each artery was treated using the DIAMONDBACK 360®
OAS (Cardiovascular Systems, Inc., Saint Paul, MN) with Solid Crowns
(1.25–2.0 mm), delivered as 3 consecutive OAS runs, at 60,000 rpm,
90,000 rpm and 120,000 rpm in 60–140 mm long lesions
(91.7 ± 6.7 mm).
After OAS treatment, arteries were harvested and divided into
2–8 cm long tubular segments. Each segment was annotated relative to
the location of the OAS treatment site, and assigned for histology,
scanning electron microscopy (SEM), or drug incubation with 14C-la-
beled paclitaxel for drug uptake analysis or ﬂuorescent labeled pacli-
taxel for drug distribution analysis as described below (Fig. 1). Seg-
ments assigned for drug incubation were retrospectively scored for
circumferential calcium burden based on 3-D images or angiography.
Following Fanelli et al. [7], a score of 1–4 was assigned based on the
number of quadrants exhibiting substantial calciﬁcation.
2.2. Drug incubation
Freshly excised arterial segments (3–8 cm long) originating from
OAS-treated or untreated sites were trimmed to reduce edge eﬀects,
ligated with suture at one end (as were any side branches) and lu-
menally infused with a buﬀered solution (PBS/4% BSA) of radiolabeled
(14C, 10 μM) or ﬂuorescent (Oregon Green 488, 10 μM) paclitaxel. Fully
infused arterial segments were ligated in the open end and incubated in
50 mL PBS/4% BSA (37 °C) in a shaking water bath. After 1 h, in-
cubated segments were rinsed with PBS to remove residual unbound
drug, and processed for scintillation counting or ﬂuorescent micro-
scopy.
2.3. Analysis of radiolabeled drug uptake
After drug infusion, the sutured ends of each vessel were cut away,
and the artery ﬂushed with PBS to remove residual, unbound 14C pa-
clitaxel (Fig. 2A). Wash and incubation solution volumes were recorded
for each artery and analyzed for isotope activity. The sutured ends and
remaining segment (∼1.5–2.5 cm) of each artery were weighed and
incubated in excess Solvable® (Perkin Elmer) at 37 °C in a shaking
water bath. Digested samples were analyzed for 1–2 min for isotope
activity in a liquid scintillation counter. Scintillation counts were con-
verted to drug weight and divided by tissue weight to obtain the bulk
tissue content for each artery. Drug tissue content (Mtissue) was nor-
malized to the (leakage corrected) infused drug dose (Mdose), and con-
trasted with the diﬀusion-binding model predicted uptake kinetics from
a ﬁnite volume (Fig. 2B):











is a bulk absorption rate-constant, Deﬀ is the eﬀective diﬀusion coeﬃ-
cient of drug in the penetrated tissue layer, kp is the equilibrium par-
tition coeﬃcient of the drug in the tissue, fu is the fraction of free drug
in the infusate, Vlumen is the volume of infusate and Amural is the mural
surface area of the tissue, estimated by assuming a cylindrical lumen.
The derivation and numerical validation of Eqs. (1–2) is detailed in the
Supplemental methods (Figs. S1–S4). Evaluation of the right hand side
of Eq. (1) at t= 1 h provided an estimate of the bulk absorption rate-
constant kabsorb. For an inhomogeneous tissue, supplemental numerical
Fig. 1. Experimental paradigm. Representative angiographic image (bottom) of the fe-
moropopliteal artery illustrating treatment location and vessel segmentation. Segments
assigned for ﬂuorescent or radiolabeled drug infusion are demarcated by arrows (blue)
and their corresponding calcium burden depicted in reconstructed 3-D images (top).
Inserts depict cross section views along green demarcation arrows. (For interpretation of
the references to colour in this ﬁgure legend, the reader is referred to the web version of
this article.)
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simulations illustrate that the estimated kabsorb is representative of the
spatially averaged eﬀective diﬀusion coeﬃcient (Fig. S4C, Supple-
mental methods).
2.4. Analysis of ﬂuorescent drug distribution
After drug infusion, the sutured ends of each vessel were excised
and discarded. The remaining artery segments were ﬂushed with PBS
and embedded in OCT tissue freeze medium and snap frozen.
Embedded arterial segments were cryosectioned to yield 0.010 mm
thick parallel cross-sections with a cryostat (Thermo Electron Cryotome
SME, Waltham, Massachusetts, USA), stored at −20 °C, and subse-
quently imaged on an OLYMPUS BX60 epiﬂuorescence microscope
running cellSens 1.4 (Olympus Optical Corporation, Ltd., Tokyo,
Japan).
Using ImageJ (NIH, Bethesda, Maryland, USA) the lumen of images
of ﬂuorescent arterial sections was extracted, a luminal centroid esti-
mated, and a zero intensity baseline established to account for auto-
ﬂuorescence. Fluorescent drug intensity proﬁles were assessed in 10°
increments circumferentially. The penetration depth at each angle was
deﬁned as the distance from the lumen at which intensity declined to
10% of peak. Normalized intensity proﬁles were averaged over the
entire circumferential arc to obtain representative transmural
distributions, I(x) where x is the distance from the extracted lumen and
ﬁt to the bell-shaped pattern predicted by a binding-diﬀusion model





I x t x
D t




The derivation and numerical validation of Eq. (3) is provided in the
Supplemental methods. For an inhomogeneous tissue, supplemental
numerical simulations predict an exponential-like distribution that
when ﬁt to Eq. (3) provides an estimate of the spatially averaged ef-
fective diﬀusion coeﬃcient (Fig. S4F, Supplemental methods).
2.5. Histopathology and morphometry
Tubular segments (1–3 cm long) of untreated or OAS-treated ar-
teries adjacent to 14C-paclitaxel infused segments were formalin-ﬁxed,
resin embedded, step-sectioned at 5 μm, and stained with hematoxylin
and eosin (H & E), and Movat pentachrome (MP). Qualitative para-
meters were assessed circumferentially in 30° arc increments as follows:
Predominate neointimal morphology - (1) smooth muscle cells, (2) ground
substance/mucinous elements, (3) ﬁbrous tissue, (4) calciﬁed, or (5)
mixed morphology; Mural (i.e., neointima and tunica media combined)
and Tunica Media Calciﬁcation - (1) < 25% wall thickness, (2) 25–50%
wall thickness, (3) 50–75% wall thickness, (4) 100% wall thickness.
Based on the incidence of neointimal calciﬁcation scores (i.e., a Score 4
as above), the circumferential extent of calciﬁcation was graded as (0)
absence, (1) 0–25% of circumference, (2) 25–50%, (3) 50–75%, (4)
75–100%. Post-ﬂuorescent analysis, frozen arterial sections were for-
malin-ﬁxed and stained with H& E and/or MP. Using the approximate
luminal centroid quantitative measurements of neointima and tunica
media thickness were obtained circumferentially in 10° increments.
2.6. SEM
Arterial samples (3–5 cm long) explanted from transition regions
that included both untreated and treated segments (Fig. 1) were ﬁxed in
2.5% glutaraldehyde and bisected longitudinally. Hemisections were
rinsed with 0.1 M sodium cacodylate buﬀer, post-ﬁxed in 1% osmium
tetroxide in 0.1 M sodium cacodylate buﬀer, rinsed with 0.1 M sodium
cacodylate buﬀer and DI water, dehydrated in a graded series of alcohol
solutions, dried using a critical point dryer, mounted onto metallic
mounts, metal ion sputter coated, then examined and imaged at a range
of magniﬁcations with SEM (Hitachi, S3400-NII).
2.7. Statistics and data analysis
All data are presented as the mean ± standard error. Data ﬁts to
Eqs. (1 and 3) were performed using Matlab (MathWorks, Natick, MA,
USA). Data were pooled either per segment, section or sector when
considered appropriate. For all statistical tests, datasets were ﬁrst as-
sessed for normality using a Shapiro-Wilk test. For pairwise compar-
isons of continuous data, if normality was met, a t-test was conducted;
otherwise, a Mann-Whitney rank sum test was performed. Ordinal data
(calciﬁcation scores) was compared using Mann-Whitney Rank Sums
test. All statistical analyses were performed using Sigmaplot for Win-
dows (Systat Software, San Jose, CA, USA) and the null hypothesis of no
diﬀerence was only rejected if the value of the calculated statistic was
(p < 0.05).
3. Results
Complimentary drug infusion experiments assessed OAS treatment
eﬀects on drug delivery. Infusion of 14C-paclitaxel solutions enabled
quantiﬁcation of bulk drug absorption and its dependence on quadrant
calciﬁcation scores (in 10 untreated and 9 OAS-treated segments). By
Fig. 2. Schematic of diﬀusion-partitioning controlled arterial drug uptake and distribu-
tion. (A) Schematic of an excised arterial segment infused with drug solution and both
ends were closed. Vlumen is the lumen volume and Amural is the surface area of the infusate/
tissue interface (B) High magniﬁcation cross sectional view of the lumen and arterial
media, illustrating the key processes and equations governing drug distribution from a
well-mixed infusate volume (Vlumen). In the lumen, a fraction fu, if the drug is free and the
remainder is bound to albumin. Only free drug is absorbed by the artery wall. Once in the
tissue, free drug diﬀuses with diﬀusion coeﬃcient D or binds nonspeciﬁcally to tissue
proteins with partition coeﬃcient kp. Drug distribution is dominated by the eﬀective
diﬀusion coeﬃcient Deﬀ (Eq. (3)) whereas total drug uptake is also governed by the
partition coeﬃcient, lumen volume, mural area and the fraction of free drug (Eqs. (1–2)).
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contrast, infusion of ﬂuorescently labeled drug solution enabled the
quantiﬁcation of distribution proﬁles and penetration depth relative to
tissue ultrastructure markers (in untreated and 5 OAS-treated seg-
ments). Analysis of 3-D images and angiography revealed that femor-
opopliteal arterial segments assigned for radiolabeled drug infusion
appeared less calciﬁed than those assigned for ﬂuorescent drug infusion
(1.9 ± 0.3 quadrants [absorption] vs 3.4 ± 0.3 quadrants [distribu-
tion], p = 0.006). Hence, though results from uptake and distribution
studies are qualitatively similar and complimentary, the two data sets
cannot be directly combined.
3.1. The eﬀect of OAS treatment on arterial morphology and bulk drug
absorption
The histopathologic appearance of untreated control femor-
opopliteal (n = 5) and control tibial (n = 2) segments was consistent
with the morphology of atherosclerotic disease as typiﬁed by variable
disruption of normal arterial architecture, frequent eﬀacement/loss of
the tunica media, and plaque formation (Fig. 3A–C). Neointimal mor-
phology was predominately collagenous/ﬁbrous with varying lesser
amounts of smooth muscle inﬁltration, extracellular matrix (i.e., pro-
teoglycans), lipid, and/or calciﬁcation with highly variable thickness
which was, on average, greatest in the popliteal segment. Plaque cal-
ciﬁcation in the popliteal segment was 2.7- and 4.6-fold greater relative
to the SFA (p < 0.001) and tibial (p < 0.001) arteries, respectively.
Medial calciﬁcation was observed in two tibial segments (6.4-fold re-
lative to femoropopliteal segments, p < 0.001). Regardless of artery,
enface SEM of the luminal surface of untreated segments revealed
variable endothelial coverage (Fig. 3Ai–Ci). Plaque modiﬁcations re-
lated to OAS-treatment were evident by light microscopy of stained
cross sections and enface SEM and characterized by variable denuda-
tion of endothelium and focally extensive disruption of subendothelial
calciﬁed plaque (Fig. 3D–F). Relative to untreated controls, OAS-treated
femoropopliteal segments exhibited decreases in plaque thickness
(569.1 ± 17.7 μm [control] vs. 386.3 ± 12.9 μm [OAS], p < 0.001)
and calciﬁed circumferential arc (19.0 ± 4.9% [control] vs
10.5 ± 2.8% [OAS], p = 0.163).
Bulk absorption of 14C paclitaxel in untreated segments was highly
variable, ranging from 0.07–2.16 ng/mg (0.92 ± 0.22 ng/mg,
n = 10). In OAS-treated segments, bulk paclitaxel absorption ranged
from 0.52–2.49 ng/mg and trended 50% higher relative to untreated
segments (1.38 ± 0.20 ng/mg, n = 9, p = 0.147). Model based in-
terpretation of tissue uptake normalized to perfusate dose (via Eq. (1))
provided insights into the dependence of the bulk absorption rate-
constant of 14C paclitaxel (Eq. (2)) on calciﬁcation scores and treat-
ment. In untreated femoropopliteal segments the bulk absorption rate-
constant decreased exponentially (5.5-fold per calciﬁed quadrant) with
increased calcium scores (p = 0.05, n = 7) (Fig. 4). Moreover, pacli-
taxel absorption rates-constants were 461 ± 451 fold higher in seg-
ments of the same artery when treated with OAS vs untreated Thus, the
degree of circumferential calciﬁcation predicts arterial drug uptake and
explains the large variability in this experimental cohorts.
Fig. 3. OAS treatment aﬀects neointimal morphology.
Representative MP stained cross sections (A–F) and
matching enface SEM (Ai–Fi) of untreated (A–C) and OAS-
treated (D–Fi) artery segments. (A, D) the SFA, (B, E) po-
pliteal arteries, (C, F) tibial arteries.
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3.2. Untreated arterial morphology and drug distribution proﬁles
Histologic assessment was performed on frozen sections to allow for
co-registration of ﬂuorescent drug distribution in the same tissue sec-
tion. Untreated tissue segments used for ﬂuorescent infusion studies
revealed similarly developed atherosclerotic plaque morphologies
(Fig. 5A–C). In femoropopliteal and tibial segments, ﬂuorescent in-
tensity peaked at the luminal interface and exhibited large circumfer-
ential gradients that appeared to track with tissue morphology
(Fig. 5Ai–Bi). Transmural ﬂuorescent intensities declined to 10% of
peak intensity within the plaque, 85.1 ± 2.1 μm from the luminal in-
terface for SFA (415 sectors), 67.6 ± 2.3 μm for popliteal (381 sectors)
and 48.0 ± 1.7 μm for tibial segments (203 sectors). Distribution
curves appeared more exponential than bell-shaped (Fig. 5Aii–Cii)
consistent with a linearly increasing eﬀective diﬀusion coeﬃcient
(Supplemental Methods, Fig. S4), with spatial averages of
1.99 ± 0.27 × 10−9 cm2/s in the SFA (48 quadrants),
1.29 ± 0.21 × 10−9 cm2/s in popliteal (44 quadrants) and
0.59 ± 0.07 × 10−9 cm2/s in tibial segments (24 quadrants).
3.3. The eﬀect of OAS treatment on drug distribution proﬁles
Qualitatively similar ﬂuorescent distribution patterns were ob-
served in OAS-treated arteries (Fig. 6), with deepest penetration in the
SFA (102.4 ± 2.1 μm, 895 sectors), 20% less in popliteal
(81.7 ± 2.8 μm, 317 sectors, p < 0.001) and 50% less in tibial seg-
ments (50.2 ± 1.7 μm, 306 sectors, p < 0.001). Transmural dis-
tribution curves appeared more exponential than bell-shaped
(Fig. 6Aii–Bii), consistent with a linearly increasing eﬀective diﬀusion
coeﬃcient (Supplemental methods, Fig. S4). OAS treated femor-
opopliteal segments exhibited 26% deeper paclitaxel penetration
(p < 0.001) and a 70% larger eﬀective diﬀusion coeﬃcient compared
to untreated segments (2.85 ± 0.25 × 10−9 cm2/s [treated] vs
1.66 ± 0.18 × 10−9 cm2/s [untreated], p < 0.001). In tibial seg-
ments, the estimated eﬀective diﬀusion coeﬃcient was unchanged by
OAS treatment (0.64 ± 0.06 × 10−9 cm2/s [treated] vs
0.59 ± 0.07 × 10−9 cm2/s [untreated], p = 0.6).
4. Discussion
Arterial calciﬁcation has long been associated with poorer outcomes
for endovascular drug delivery yet it remains unclear whether this is
due to stent malapposition or hindrance of drug penetration and dis-
tribution after local release. Ex-vivo drug infusions of calciﬁed arteries
as in the current study provide a controlled model by which to directly
study lesion barrier eﬀects on drug distribution with and without lesion
modiﬁcation. Treated segments exhibited a trend for 50% greater 14C-
paclitaxel uptake of relative to control segments (1.38 ± 0.20 vs
0.92 ± 0.22 ng/mg, p = 0.147). Treatment of femoropopliteal seg-
ments was associated with a∼ 180 μm reduction in plaque thickness
(p < 0.001) and a 45% reduction in circumferential intimal calciﬁ-
cation (from 19.0 to 10.5%, p = 0.163). These ﬁndings are well aligned
with echogenicity analysis of IVUS estimated that OAS decreased the
calciﬁed area in the coronary artery of an arteriosclerosis obliterans
patient by 58% [16] (from 11.0 to 4.6%). In concordance with these
ﬁndings, ﬂuorescent paclitaxel penetrated 26% deeper in OAS treated
femorpopliteal segments compared to controls (p < 0.001).
4.1. Mechanistic interpretation of experiments
A deeper understanding of the relationship between the two ex-vivo
data sets and their signiﬁcance to therapeutic scenarios was aﬀorded
via the development of a predictive model of arterial drug distribution
based on the mechanism of diﬀusion and binding. The focus on these
two processes was motivated by published ex-vivo and computational
studies that illustrated their dominance in determining paclitaxel dis-
tribution and retention in healthy animal arteries [17–21]. The dis-
tribution patterns of ﬂuorescent paclitaxel in human femoropopliteal
segments were well explained by these processes when accounting for
spatial variability in tissue composition, with a spatially averaged ef-
fective diﬀusion coeﬃcient of, 1.7 ± 0.2 × 10−9 cm2/s at baseline
and 70% higher in OAS-treated arteries (p < 0.001). Notably, the
published eﬀective diﬀusion coeﬃcient of paclitaxel in native porcine
iliofemoral arteries [19] (5.4 ± 3.4 × 10−7 cm2/s) is ∼300-fold the
estimate obtained in the current study, suggesting that mineralized
plaque poses a more resistive barrier to paclitaxel distribution than
healthy arterial tissue. Furthermore, the absorption rate-constant of
14C-paclitaxel in untreated femorpopliteal segments exhibited log-
linear decline with increasing calcium scores (Fig. 4), decreasing 5.5-
fold per calciﬁed quadrant. As intimal calciﬁcation is predominately
present in femoropopliteal arteries, these ﬁndings suggest that OAS
enhancement of paclitaxel distribution in current experiments was
mediated by a reduction in the degree of circumferential intimal mi-
neralization which was less present in tibial arteries.
4.2. Implications for in vivo drug delivery
In vivo arterial wall distribution and retention are determined by a
competition between binding and diﬀusion with luminal delivery and
washout. For drug-eluting stents, drug release is typically sustained and
rate limiting and washout is determined by stent geometry and degree
of strut apposition and embedding [22,23]. Inadequate stent apposition
due to calciﬁcation will increase drug washout and limit drug dis-
tribution, particularly for a slow diﬀusing drug. In contrast, drug coated
balloons present a drug-laden coating to the mural interface. Blood ﬂow
can spread this loosely adherent coating layer along the luminal in-
terface or siphon and clear drug from the treatment site, concomitant
with transmural diﬀusion of the drug into the artery wall. Thus, in-
creased resistance to paclitaxel diﬀusion within the intima will result in
increased washout and a potential reduction in eﬃcacy.
As the rate of diﬀusion scales as the square root of the eﬀective
diﬀusion coeﬃcient, the study data imply that the rate of paclitaxel
distribution in intimal plaque is ∼20-fold slower relative to healthy
tissue, which can dramatically increase the degree of washout. These
estimates imply that plaque modiﬁcation that increases tissue perme-
ability to drug will promote tissue drug retention and distribution.
Fig. 4. Paclitaxel absorption kinetics scale inversely with calciﬁcation scores. Bulk ab-
sorption rate-constants of paclitaxel (diamonds) decreased exponentially with increasing
calcium scores in control femoropopliteal arteries.
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4.3. Study limitations
The use of ex-vivo luminal drug exposures is an analytical con-
venience that does not seek to mimic the spatiotemporal dynamics of in
vivo stent and balloon based drug delivery and cannot directly account
for the presence of luminal clearance. Diﬀusion and binding of pacli-
taxel in cadaveric arterial tissue may not be fully representative of its
transport in live tissue and the quantitative validity of the ﬁndings is
further limited by the use of labeled drug analogs. Yet, previously the in
vivo drug distribution and retention following stent based and balloon
based drug delivery were modeled successfully using parameter esti-
mates derived from ex-vivo studies with radiolabeled analogs [19,24].
Similarly, though OAS treatment may diﬀerentially aﬀect plaque in live
arteries vs cadaveric arteries, the estimated reduction in calciﬁcation in
cadaveric femoropopliteal arteries (45%) is similar to the reported ef-
fects in ﬁbrocalciﬁc human coronary arteries [16].
As the main focus was on evaluation of drug delivery in calciﬁed
femoropoliteal arteries, limited observations on tibial segments and the
experimental design do not allow conclusions to be drawn as to the
inﬂuence of OAS treatment on drug transport in this diﬀerently struc-
tured anatomical and pathological vascular area. Thus, a diﬀerent set of
experiments is required to assess whether OAS aﬀects paclitaxel dis-
tribution to tibial arteries.
5. Conclusions
Both experimental and modeling data support the hypothesis that
intravascular delivery of paclitaxel is limited by the presence of calci-
ﬁed intimal plaque and may be enhanced via stromal modiﬁcation by
OAS-treatment. Whereas clinical success of atherectomy is typically
measured by the degree of debulking and luminal gain, this study de-
monstrates that even more benign modiﬁcation of calciﬁed athero-
sclerotic plaque by OAS-treatment enhances drug transfer by increasing
diﬀusion coeﬃcient, thereby signiﬁcantly enhancing adjunctive pacli-
taxel delivery. These data may explain the lack of responsiveness to
balloon based delivery of paclitaxel in highly calciﬁed peripheral ar-
teries and suggest that the eﬃcacy of such treatments may be safely
enhanced via OAS treatment.
5.1. Clinical perspectives










Fig. 5. Morphology and drug distribution of representative untreated arterial segments. Representative MP stained frozen sections of the SFA (A) popliteal (B) and tibial (C) arteries from
a single leg; neointima thicknesses are respectively 372 ± 166 μm (A), 737 ± 704 μm (B) and 111 ± 44 μm (C). Corresponding ﬂuorescent micrographs (Ai, Bi, Ci) and normalized
circumferentially averaged intensity plots (Aii, Bii, Cii) are depicted (black lines) to the right of each micrograph along with best ﬁt diﬀusion-binding predictions (red line, Eq. (3)). Best-
ﬁt eﬀective diﬀusivities are respectively 1.90 × 10−9 cm2/s (A), 1.25 × 10−9 cm2/s (B) and 0.71 × 10−9 cm2/s (C). (For interpretation of the references to colour in this ﬁgure legend,
the reader is referred to the web version of this article.)
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treating peripheral artery disease, but calciﬁc atherosclerosis remains a
major and unexplained challenge to endovascular drug delivery treat-
ments. More detailed knowledge of the barriers to drug distribution in
diseased peripheral arteries forces derived from cadaveric models might
be useful in guiding local drug delivery interventions in patients with
calciﬁed plaque to yield more consistent antirestenotic eﬀects.
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